Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoster vaccine recombinant (GSK)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Herpes zoster vaccine recombinant, adjuvanted (brand name: Shingrix) is a non-live, recombinant subunit vaccine developed by GSK for the prevention of herpes zoster (shingles) and its complications, such as postherpetic neuralgia. The vaccine consists of the Varicella Zoster Virus (VZV) glycoprotein E (gE) antigen, which is the most abundant glycoprotein expressed by VZV-infected cells, combined with the AS01B adjuvant system. AS01B is a liposome-based adjuvant containing 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and QS-21, designed to enhance the CD4+ T-cell and antibody-mediated immune response. It is administered as a two-dose intramuscular series and is indicated for adults aged 50 years and older, as well as immunocompromised adults aged 18 years and older.
- Brand names
- Shingrix
- Other names
- herpes zoster vaccine recombinant, adjuvantedrecombinant zoster vaccine
02
Targets
TLR4 (Toll-like receptor 4)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)gE (VZV glycoprotein E)
Beyond the preview
Go deeper on zoster vaccine recombinant (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoster vaccine recombinant (GSK).